Pharmacokinetics of Morphine, Morphine-3-Glucuronide and Morphine-6-Glucuronide in Terminally Ill Adult Patients

Clinical Pharmacokinetics

Volumn 55, Issue 6, 2016, Pages 697-709

  Franken, Linda G ^a   Masman, Anniek D ^b,c   de Winter, Brenda C M ^a   Koch, Birgit C P ^a   Baar, Frans P M ^b   Tibboel, Dick ^c   van Gelder, Teun ^a   Mathot, Ron A A ^d  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Palliative Care Centre   (Netherlands)

^c SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; MORPHINE; MORPHINE 3 GLUCURONIDE; MORPHINE 6 GLUCURONIDE; MORPHINE DERIVATIVE; MORPHINE-3-GLUCURONIDE; MORPHINE-6-GLUCURONIDE; NARCOTIC ANALGESIC AGENT; SERUM ALBUMIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BOLUS INJECTION; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MALE; OBSERVATIONAL STUDY; PAIN; PHARMACOKINETICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; TANDEM MASS SPECTROMETRY; TERMINALLY ILL PATIENT; VERY ELDERLY; VOLUME OF DISTRIBUTION; BIOLOGICAL MODEL; COMPUTER SIMULATION; METABOLIC CLEARANCE RATE; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; COMPUTER SIMULATION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; MORPHINE; MORPHINE DERIVATIVES; PROSPECTIVE STUDIES; SERUM ALBUMIN; TERMINALLY ILL;

EID: 84951990792     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-015-0345-4     Document Type: Article

References (42)

1. World Health Organization. Essential medicines in palliative care: executive summary. Geneva: World Health Organization; 2013.
2. Masman AD, van Dijk M, Tibboel D, Baar FP, Mathot RA. Medication use during end-of-life care in a palliative care centre. Int J Clin Pharm. 2015;37(5):767–75.
3. Portenoy RK, Thaler HT, Inturrisi CE, Friedlander-Klar H, Foley KM. The metabolite morphine-6-glucuronide contributes to the analgesia produced by morphine infusion in patients with pain and normal renal function. Clin Pharmacol Ther. 1992;51(4):422–31.
4. Milne RW, Nation RL, Somogyi AA. The disposition of morphine and its 3- and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine. Drug Metab Rev. 1996;28(3):345–472.
5. Klimas R, Mikus G. Morphine-6-glucuronide is responsible for the analgesic effect after morphine administration: a quantitative review of morphine, morphine-6-glucuronide, and morphine-3-glucuronide. Br J Anaesth. 2014;113(6):935–44.
6. Lewis SS, Hutchinson MR, Rezvani N, Loram LC, Zhang Y, Maier SF, et al. Evidence that intrathecal morphine-3-glucuronide may cause pain enhancement via toll-like receptor 4/MD-2 and interleukin-1beta. Neuroscience. 2010;165(2):569–83.
7. Christrup LL. Morphine metabolites. Acta Anaesthesiol Scand. 1997;41(1 Pt 2):116–22.
8. Morita T, Tei Y, Inoue S. Impaired communication capacity and agitated delirium in the final week of terminally ill cancer patients: prevalence and identification of research focus. J Pain Symptom Manage. 2003;26(3):827–34.
9. van Herk R, van Dijk M, Baar FP, Tibboel D, de Wit R. Observation scales for pain assessment in older adults with cognitive impairments or communication difficulties. Nurs Res. 2007;56(1):34–43.
10. Breitbart W, Strout D. Delirium in the terminally ill. Clin Geriatr Med. 2000;16(2):357–72.
11. Rietjens J, van Delden J, Onwuteaka-Philipsen B, Buiting H, van der Maas P, van der Heide A. Continuous deep sedation for patients nearing death in the Netherlands: descriptive study. BMJ. 2008;336(7648):810–3.
12. Stevenson J, Abernethy AP, Miller C, Currow DC. Managing comorbidities in patients at the end of life. BMJ. 2004;329(7471):909–12.
13. Trobec K, Kerec Kos M, von Haehling S, Springer J, Anker SD, Lainscak M. Pharmacokinetics of drugs in cachectic patients: a systematic review. PLoS One. 2013;8(11):e79603.
14. Kemik O, Sumer A, Kemik AS, Hasirci I, Purisa S, Dulger AC, et al. The relationship among acute-phase response proteins, cytokines and hormones in cachectic patients with colon cancer. World J Surg Oncol. 2010;8:85.
15. Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Rixe O, et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer. 2007;110(6):1376–84.
16. Integraal Kankercentrum Nederland. Dyspnoea: nationwide guideline. Version 2.0. http://www.pallialine.nl. Accessed Apr 2015.
17. Integraal Kankercentrum Nederland. Pain: nationwide guideline. Version 2.0. http://www.pallialine.nl. Accessed Apr 2015.
18. Ellershaw J, Ward C. Care of the dying patient: the last hours or days of life. BMJ. 2003;326(7379):30–4.
19. Campbell CF, Mason JB, Weiler JM. Continuous subcutaneous infusion of morphine for the pain of terminal malignancy. Ann Intern Med. 1983;98(1):51–2.
20. Starlander J, Melin-Johansson C, Jonsson H, Axelsson B. Oral-parenteral conversion factor for morphine in palliative cancer care: a prospective randomized crossover pilot study. Pain Res Treat. 2011;2011:504034.
21. Meineke I, Freudenthaler S, Hofmann U, Schaeffeler E, Mikus G, Schwab M, et al. Pharmacokinetic modelling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine. Br J Clin Pharmacol. 2002;54(6):592–603.
22. Hasselstrom J, Sawe J. Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations. Clin Pharmacokinet. 1993;24(4):344–54.
23. Lötsch J, Skarke C, Schmidt H, Liefhold J, Geisslinger G. Pharmacokinetic modeling to predict morphine and morphine-6-glucuronide plasma concentrations in healthy young volunteers. Clin Pharmacol Ther. 2002;72(2):151–62.
24. Comets E, Brendel K, Mentre F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed. 2008;90(2):154–66.
25. Ahn JE, Karlsson MO, Dunne A, Ludden TM. Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn. 2008;35(4):401–21.
26. Glare PA, Walsh TD. Clinical pharmacokinetics of morphine. Ther Drug Monit. 1991;13(1):1–23.
27. Hunt A, Joel S, Dick G, Goldman A. Population pharmacokinetics of oral morphine and its glucuronides in children receiving morphine as immediate-release liquid or sustained-release tablets for cancer pain. J Pediatr. 1999;135(1):47–55.
28. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247–54.
29. Säwe J, Dahlstrom B, Paalzow L, Rane A. Morphine kinetics in cancer patients. Clin Pharmacol Ther. 1981;30(5):629–35.
30. Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64(12):1147–61.
31. Patwardhan RV, Johnson RF, Hoyumpa A Jr, Sheehan JJ, Desmond PV, Wilkinson GR, et al. Normal metabolism of morphine in cirrhosis. Gastroenterology. 1981;81(6):1006–11.
32. Le Couteur DG, McLean AJ. The aging liver. Drug clearance and an oxygen diffusion barrier hypothesis. Clin Pharmacokinet. 1998;34(5):359–73.
33. Ahlers SJGM, Peeters MYM, van Gulik L, van Dongen EPA, Dahan A, Tibboel D, et al. Glucuronidatie en eliminatie van morfine bij intensivecarepatiënten: een vergelijking met gezonde vrijwilligers. Pharm Weekbl. 2014;8–9:166–71.
34. Poulain P, Hoskin PJ, Hanks GW, A-Omar O, Walker VA, Johnston A, et al. Relative bioavailability of controlled release morphine tablets (MST continus) in cancer patients. Br J Anaesth. 1988;61(5):569–74.
35. Ohde S, Hayashi A, Takahasi O, Yamakawa S, Nakamura M, Osawa A, et al. A 2-week prognostic prediction model for terminal cancer patients in a palliative care unit at a Japanese general hospital. Palliat Med. 2011;25(2):170–6.
36. Maltoni M, Caraceni A, Brunelli C, Broeckaert B, Christakis N, Eychmueller S, et al. Prognostic factors in advanced cancer patients: evidence-based clinical recommendations. A study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol. 2005;23(25):6240–8.
37. Ellershaw J. Care of the dying: what a difference an LCP makes! Palliat Med. 2007;21(5):365–8.
38. Osborne R, Joel S, Grebenik K, Trew D, Slevin M. The pharmacokinetics of morphine and morphine glucuronides in kidney failure. Clin Pharmacol Ther. 1993;54(2):158–67.
39. Faura CC, Collins SL, Moore RA, McQuay HJ. Systematic review of factors affecting the ratios of morphine and its major metabolites. Pain. 1998;74(1):43–53.
40. McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39(5):534–40.
41. Woo J, Chan HS, Or KH, Arumanayagam M. Effect of age and disease on two drug binding proteins: albumin and alpha-1-acid glycoprotein. Clin Biochem. 1994;27(4):289–92.
42. Bergman P, Sperneder S, Hoijer J, Bergqvist J, Bjorkhem-Bergman L. Low vitamin D levels are associated with higher opioid dose in palliative cancer patients: results from an observational study in Sweden. PLoS One. 2015;10(5):e0128223.